Sin conexión a internet: se muestra la versión guardada de la página.

Insight Molecular…

USUSD
← Al Screener

Insight Molecular Diagnostics Inc. (LSE:0KCC) — Biotechnology: In Vitro & In Vivo Diagnostic Substances. Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
imdxinc.com
Relaciones con los Inversores
investors.imdxinc.com/
Sector
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sede Central
NASHVILLE, United States
Consejero Delegado
Joshua Riggs
Empleados
55
Cotiza Desde
29.01.2018 (LSE:0KCC)
Acciones en Circulación
32.72 M a 2026-08-03
Capital Flotante
9.98 M
Capitalización Bursátil
110.28 M USD
Insiders
21%
Inversores Institucionales
56.5%
Industria (SIC)
In Vitro & In Vivo Diagnostic Substances
P/E
pérdidas
Ratio de Reparto
pérdidas
FCF
−31.0 M USD
Pagos / FCF
FCF < 0
Deuda
1.87 M USD
caja neta
Racha de Dividendos
—
Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
NAV
−0.65 USD
Fecha del Balance30.06.2026
Activos29.4 M USD
− Pasivos50.7 M USD
= NAV (patrimonio de los accionistas de la empresa)−21.3 M USD
= NAV Tangible−21.3 M USD
Acciones32 622 884
NAV por Acción−0.65 USD
NAV Tangible por Acción−0.65 USD
El patrimonio es negativo: los pasivos superan los activos (a menudo debido a grandes recompras de acciones). El P/NAV no se calcula.
Historial del NAV
Fecha del BalanceNAVNAV por Acción
30.06.2026−21.3 M USD−0.65 USD
31.03.2026−10.7 M USD−0.33 USD
31.12.2025−31.5 M USD−1.10 USD
30.09.2025−9.20 M USD−0.32 USD
30.06.20251.10 M USD0.04 USD
31.03.202510.2 M USD0.36 USD
31.12.2024−12.3 M USD−0.70 USD
30.09.20249.71 M USD0.73 USD
Descripción

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksIMDX principalUSD3.06 +9.68%acciones ordinarias
LSE London Stock Exchange0KCC IOBUSD3.5317 +0.00%acciones ordinarias

Precio en 3 Meses

día alcista día bajista fecha ex-dividendo fecha de pagoPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Dividendos

No se han encontrado pagos de dividendos (comprobado el 19.10.2026). Es probable que la empresa no reparta dividendos.

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Broadwood Capital, Inc.38.76%12.68 M2026-06-30
AWM Investment Company,…8.67%2.84 M2026-06-30
Vanguard Capital Managem…2.25%735 8472026-06-30
Pura Vida Investments, L…1.48%484 8452026-06-30
VANGUARD INDEX FUNDS-Van…1.45%475 4052026-06-30
Family Office Research L…1.13%368 8492026-06-30
Geode Capital Management…0.79%256 9032026-06-30
VANGUARD INDEX FUNDS-Van…0.76%248 0592026-06-30
JAMES ANDREA S. (Chief F…≈0.63%206 0602026-03-26
ARNO ANDREW (Director)≈0.56%184 4932026-06-11
FNY Investment Advisers,…0.56%182 5612026-06-30
Jane Street Group, LLC0.48%157 6822026-06-30
Blackrock Inc.0.46%150 5212026-06-30
Vanguard Fiduciary Trust…0.38%124 5762026-06-30
Fidelity Concord Street…0.33%108 0232026-07-31
LAST ANDREW J (Director)≈0.2%66 4522026-06-11
SILVERMAN LOUIS E (Direc…≈0.19%63 5072026-06-11
iShares Trust-iShares Mi…0.13%42 9712026-08-31
Fidelity Concord Street…0.12%38 6222026-07-31
RIGGS JOSHUA (Chief Exec…≈0.12%38 3652026-03-26
Fidelity Concord Street…0.11%36 1252026-07-31
Fidelity Concord Street…0.06%19 4922026-07-31
VANGUARD VALLEY FORGE FU…0.02%7 9272026-06-30
LIU JAMES YANG (Officer…≈0.01%3 7112026-03-26
VANGUARD Inst. INDEX Fd.…0.01%4 4562026-06-30
EQ Advisors Trust-1290 V…0.01%2 9022026-06-30
BROADWOOD PARTNERS, L.P.…——2026-04-27
SMITH PATRICK W. (Benefi…——2025-02-07